No abstract

Background: At present, most of the targeted therapies for thyroid carcinoma are in the clinical trial stage, and there is still no strong evidence to confirm their clinical effect. The aim of this meta-analysis was to evaluate the outcome of targeted therapies and provide quantitative evidence.Method: Ovid, PubMed, EMBAS, ClinicalTrails.gov, and Cochrane Library electronic databases were searched until September 1, 2019. Randomized controlled studies (RCTs) studies that compared the treatment of thyroid carcinoma with the targeted therapies of utility and complications were analyzed.Results: The study included 5 studies with a total of 1,615 patients, with 991 cases in the drug group and 624 cases in the placebo group. The meta-analysis indicated that compared with the placebo group, the progression-free survival (PFS) rate of the drug group was significantly improved. The PFS of the drug group was 10.8 to 30.5 months, compared with 4 to 19.3 months for the placebo group (6 months PFS:

Background: Papillary thyroid carcinoma and follicular thyroid carcinoma are both well-differentiated thyroid carcinomas. Here, we aimed to establish and evaluate a nomogram for patients with differentiated thyroid cancer.Methods: Patient records were available from SEER database. We enrolled 17,659 patients in total and randomly separated them into a modeling cohort (n = 12,363, 70%) and a validation cohort (n = 5,296, 30%). Predictive models were established via univariate and multivariate Cox regression analysis of potential risk factors and used to produce a nomogram. Performance of the nomograms in terms of discrimination ability and calibration was evaluated by determining the concordance index (C-index) and by generating calibration plots, respectively, using the internal (modeling cohort) and external (validation cohort) validity.Results: Seven independent prognostic factors (age, race, sex, grade, AJCC T stage, AJCC N stage, and AJCC M stage) were identified and used to develop the nomogram for OS prediction of patients with DTC. The C-index for the modeling cohort was 0.829 (95% CI: 0.807-0.851), and the C-index for the validation cohort was 0.833 (95% CI: 0.803-0.862). Calibration plots of the nomogram indicated acceptable agreement between the predicted 3-, 5-year survival rates and the actual observations in the modeling and validation groups.Conclusions: We have constructed and verified a nomogram containing clinical factors, which showed better prognostic judgment and predictive accuracy for DTC. This will enable clinicians and patients to easily personalize and quantify the probability of DTC during the postoperative period.

No abstract